Astra-Oxford Vaccine Stays Near Front of Line Despite U.S. Delay
- Trial resumed weeks after it was halted due to an illness
- Increased coronavirus infection rates help studies advance
This article is for subscribers only.
A seven-week halt to a U.S. trial of the Covid vaccine developed by AstraZeneca Plc and the University of Oxford bumped it from pole position in the race for a protective shot, but it’s still in the leading pack.
High rates of infection as the pandemic regains strength and the large numbers of participants in other trials around the world should help keep the vaccine program on course, according to scientists.